Superior glycaemic control with semaglutide across SUSTAIN 1-5 clinical trials

被引：0
|
作者：
Ahmann, A. [1 ]
Chow, F. [2 ]
Fonseca, V. [3 ]
Mehta, R. [4 ]
Thomsen, H. F. [5 ]
Thielke, D. [5 ]
Petrie, J. [6 ]
机构：
[1] Harold Schnitzer Diabet Hlth Ctr, Portland, OR USA
[2] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China
[3] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
[4] Natl Inst Med Sci & Nutr, Mexico City, DF, Mexico
[5] Novo Nordisk AS, Soborg, Denmark
[6] Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
816
引用
收藏
页码：S377 / S377
页数：1
相关论文
共 50 条
  • [1] Semaglutide provides superior glycaemic control across SUSTAIN 1-5 clinical trials
    Petrie, J.
    Chow, F.
    Fonseca, V.
    Mehta, R.
    Thomsen, H. F.
    Thielke, D.
    Ahmann, A.
    DIABETIC MEDICINE, 2018, 35 : 83 - 83
  • [2] Semaglutide Provides Superior Glycemic Control across SUSTAIN 1-5 Clinical Trials
    Imamine, Rui
    Satou, Ai
    Mase, Hajime
    Mizoguchi, Asako
    Minatoguchi, Makiko
    Kusama, Minoru
    Watarai, Atuko
    Kawamura, Takahiko
    Hotta, Nigishi
    Nakashima, Eitaro
    DIABETES, 2017, 66 : A285 - A285
  • [3] Semaglutide Provides Superior Body Weight Reduction across SUSTAIN 1-5 Clinical Trials
    Lingvay, Ildiko
    Luedemann, Joerg
    Marre, Michel
    Uusinarkaus, Kari
    Woo, Vincent
    Thomsen, Henrik F.
    Wijayasinghe, Nelun
    Davies, Melanie
    DIABETES, 2017, 66 : A64 - A64
  • [4] Semaglutide provides superior body weight reduction across SUSTAIN 1-5 clinical trials
    Davies, M. J.
    Luedemann, J.
    Marre, M.
    Uusinarkaus, K.
    Woo, V.
    Thomsen, H. F.
    Wijayasinghe, N.
    Lingvay, I.
    DIABETIC MEDICINE, 2018, 35 : 82 - 82
  • [5] Semaglutide consistently reduces both fasting and postprandial glucose levels across SUSTAIN 1-5 clinical trials
    Cariou, B.
    Unger, J.
    Jodar, E.
    Birch, S.
    Tadayon, S.
    Aroda, V. R.
    DIABETOLOGIA, 2017, 60 : S378 - S378
  • [6] Semaglutide Reduces HbA1c across Baseline HbA1c Subgroups across SUSTAIN 1-5 Clinical Trials
    Bain, Stephen
    Araki, Eiichi
    Desouza, Cyrus
    Garg, Satish
    Rose, Ludger
    Tsoukas, George
    Bergan, Eirik Q.
    Karsbol, Julie Derving
    Devries, J. Hans
    DIABETES, 2017, 66 : A298 - A299
  • [7] Semaglutide reduces HbA1c across baseline HbA1c subgroups across SUSTAIN 1-5 clinical trials
    Bain, S. C.
    Araki, E.
    DeSouza, C.
    Garg, S.
    Rose, L.
    Tsoukas, G.
    Bergan, E. Q.
    Karsbol, J. D.
    DeVries, J. H.
    DIABETIC MEDICINE, 2018, 35 : 81 - 81
  • [8] Treatment with semaglutide provides superior body weight reduction vs comparators in subjects with type 2 diabetes across the SUSTAIN 1-5 trials
    Lingvay, I.
    Luedemann, J.
    Marre, M.
    Uusinarkaus, K.
    Woo, V.
    Thomsen, H. F.
    Wijayasinghe, N.
    Davies, M.
    DIABETOLOGIA, 2017, 60 : S377 - S378
  • [9] Semaglutide Reduces Body Weight across Baseline BMI Subgroups across SUSTAIN 1-5
    Leiter, Lawrence A.
    Charpentier, Guillaume
    Chaykin, Louis
    Garvey, W. Timothy
    Warren, Mark L.
    Karsbol, Julie D.
    Thielke, Desiree
    Masmiquel, Luis
    DIABETES, 2017, 66 : A293 - A293
  • [10] Semaglutide reduces HbA1c and body weight across baseline HbA1c subgroups in the SUSTAIN 1-5 clinical trials
    Bain, S.
    Araki, E.
    Desouza, C.
    Garg, S.
    Rose, L.
    Tsoukas, G.
    Bergan, E.
    Karsbol, J. Derving
    DeVries, J.
    DIABETOLOGIA, 2017, 60 : S375 - S375
12345